215 related articles for article (PubMed ID: 33001045)
1. Diastolic blood pressure achieved at target systolic blood pressure (120-140 mm Hg) and dabigatran-related bleeding in patients with nonvalvular atrial fibrillation: A real-world study.
Yu Y; Li M; Zhou W; Wang T; Zhu L; Hu L; Bao H; Cheng X
Anatol J Cardiol; 2020 Oct; 24(4):267-273. PubMed ID: 33001045
[TBL] [Abstract][Full Text] [Related]
2. Peripheral leukocyte count and risk of bleeding in patients with non-valvular atrial fibrillation taking dabigatran: a real-world study.
Zhou W; Wang T; Zhu LJ; Wen MH; Hu LH; Huang X; You CJ; Li JX; Wu YQ; Wu QH; Bao HH; Cheng XS
Chin Med J (Engl); 2019 Sep; 132(18):2150-2156. PubMed ID: 31490268
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial.
Böhm M; Brueckmann M; Eikelboom JW; Ezekowitz M; Fräßdorf M; Hijazi Z; Hohnloser SH; Mahfoud F; Schmieder RE; Schumacher H; Wallentin L; Yusuf S
Eur Heart J; 2020 Aug; 41(30):2848-2859. PubMed ID: 32385506
[TBL] [Abstract][Full Text] [Related]
4. Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial.
Park S; Bergmark BA; Shi M; Lanz HJ; Chung N; Ruff CT; Antman EM; Braunwald E; Giugliano RP
Hypertension; 2019 Sep; 74(3):597-605. PubMed ID: 31352829
[TBL] [Abstract][Full Text] [Related]
5. Association Between the Change in Total Bilirubin and Risk of Bleeding Among Patients With Nonvalvular Atrial Fibrillation Taking Dabigatran.
Xiong Y; Hu L; Zhou W; Li M; Wang T; Huang X; Bao H; Cheng X
Clin Appl Thromb Hemost; 2020; 26():1076029620910808. PubMed ID: 32343610
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
7. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
[TBL] [Abstract][Full Text] [Related]
8. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
Kohsaka S; Murata T; Izumi N; Katada J; Wang F; Terayama Y
Curr Med Res Opin; 2017 Nov; 33(11):1955-1963. PubMed ID: 28857611
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
[TBL] [Abstract][Full Text] [Related]
10. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
Deitelzweig S; Keshishian A; Li X; Kang A; Dhamane AD; Luo X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Nadkarni A; Di Fusco M; Garcia Reeves AB; Yuce H; Lip GYH
J Am Geriatr Soc; 2019 Aug; 67(8):1662-1671. PubMed ID: 31112292
[TBL] [Abstract][Full Text] [Related]
11. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
Deitelzweig S; Bruno A; Trocio J; Tate N; Gupta K; Lin J; Lingohr-Smith M
Curr Med Res Opin; 2016; 32(3):573-82. PubMed ID: 26652179
[TBL] [Abstract][Full Text] [Related]
12. Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients.
Lamberts M; Staerk L; Olesen JB; Fosbøl EL; Hansen ML; Harboe L; Lefevre C; Evans D; Gislason GH
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28196815
[TBL] [Abstract][Full Text] [Related]
13. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
Lip GY; Keshishian A; Kamble S; Pan X; Mardekian J; Horblyuk R; Hamilton M
Thromb Haemost; 2016 Oct; 116(5):975-986. PubMed ID: 27538358
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
Korenstra J; Wijtvliet EP; Veeger NJ; Geluk CA; Bartels GL; Posma JL; Piersma-Wichers M; Van Gelder IC; Rienstra M; Tieleman RG
Europace; 2016 Sep; 18(9):1319-27. PubMed ID: 26843571
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
16. Relationship of Hypertension and Systolic Blood Pressure With the Risk of Stroke or Bleeding in Patients With Atrial Fibrillation: The Fushimi AF Registry.
Ishii M; Ogawa H; Unoki T; An Y; Iguchi M; Masunaga N; Esato M; Chun YH; Tsuji H; Wada H; Hasegawa K; Abe M; Akao M
Am J Hypertens; 2017 Nov; 30(11):1073-1082. PubMed ID: 28575205
[TBL] [Abstract][Full Text] [Related]
17. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
Lip GY; Pan X; Kamble S; Kawabata H; Mardekian J; Masseria C; Bruno A; Phatak H
Int J Clin Pract; 2016 Sep; 70(9):752-63. PubMed ID: 27550177
[TBL] [Abstract][Full Text] [Related]
18. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
Van Ganse E; Danchin N; Mahé I; Hanon O; Jacoud F; Nolin M; Dalon F; Lefevre C; Cotté FE; Gollety S; Falissard B; Belhassen M; Steg PG
Stroke; 2020 Jul; 51(7):2066-2075. PubMed ID: 32539675
[TBL] [Abstract][Full Text] [Related]
19. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
[TBL] [Abstract][Full Text] [Related]
20. Bleeding Risk of Add-On Anti-Platelet Agents to Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation (From 2216 Patients in the DIRECT Registry).
Sotomi Y; Hirata A; Amiya R; Kobayashi T; Hirayama A; Sakata Y; Higuchi Y
Am J Cardiol; 2019 Apr; 123(8):1293-1300. PubMed ID: 30717887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
